Vendor review
Xingruida XDR reviews
Xingruida XDR reviews from 92 independent lab tests (Retatrutide, Tirzepatide and Tesamorelin): grade A, purity and fill accuracy. Is Xingruida XDR legit? See what its vials showed.
Grade A92 independent lab tests0 peptides listedShips from China
Xingruida XDR's website could not be reached at the last check. Links to the shop are disabled.
What the lab tests show
92 tests on record, newest first. Scores are purity divided by ten.
| Date | Product | Purity | Quantity | Identity | Certificate |
|---|---|---|---|---|---|
| Aug 12, 2026 | Tirzepatide | 99.9 % | 29.9 mg of 30 mg (0 %) | Pass | View |
| Aug 12, 2026 | Tesamorelin | 99.9 % | 4.71 mg of 5 mg (-6 %) | Pass | View |
| Aug 12, 2026 | Retatrutide | 99.9 % | 19.1 mg of 20 mg (-4 %) | Pass | View |
| Aug 12, 2026 | Tirzepatide | 99.9 % | 30 mg of 30 mg (0 %) | Pass | View |
| Aug 12, 2026 | Ipamorelin | 99.7 % | 10.5 mg of 10 mg (5 %) | Pass | View |
| Aug 12, 2026 | Retatrutide | 99.9 % | 4.78 mg of 10 mg (-52 %) | Pass | View |
| Aug 9, 2026 | Tesamorelin | 99.6 % | 12 mg of 10 mg (20 %) | Pass | View |
| Aug 9, 2026 | TB-500 | 99.6 % | 11.9 mg of 10 mg (19 %) | Pass | View |
| Aug 9, 2026 | Retatrutide | 99.7 % | 20.8 mg of 20 mg (4 %) | Pass | View |
| Aug 3, 2026 | Tesamorelin | 99.9 % | 9.56 mg of 10 mg (-4 %) | Pass | View |
| Aug 3, 2026 | Tirzepatide | 99.6 % | 49.7 mg of 60 mg (-17 %) | Pass | View |
| Jul 30, 2026 | Retatrutide | 99.8 % | 21.1 mg of 20 mg (6 %) | Pass | View |
| Jun 16, 2026 | Tirzepatide | 99.8 % | 34.5 mg of 30 mg (15 %) | Pass | View |
| Jun 5, 2026 | Retatrutide | 99.9 % | 18.9 mg of 20 mg (-6 %) | Pass | View |
| May 27, 2026 | Tesamorelin | 99.8 % | 10.8 mg of 10 mg (8 %) | Pass | View |
| May 27, 2026 | BPC-157 | 99 % | 4.48 mg of 5 mg (-10 %) | Pass | View |
| May 27, 2026 | TB-500 | 91.5 % | 5.71 mg of 5 mg (14 %) | Pass | View |
| May 27, 2026 | Ipamorelin | 99.7 % | 5.25 mg of 5 mg (5 %) | Pass | View |
| May 25, 2026 | Retatrutide | 99.5 % | 31.9 mg of 30 mg (6 %) | Pass | View |
| May 15, 2026 | Tirzepatide | 99.7 % | 37.9 mg of 40 mg (-5 %) | Pass | View |
| May 13, 2026 | GHK-Cu | 99.9 % | 51.9 mg of 100 mg (-48 %) | Pass | View |
| May 8, 2026 | Retatrutide | 99.9 % | 10.6 mg of 20 mg (-47 %) | Pass | View |
| Mar 13, 2026 | Retatrutide | 99.8 % | 16.1 mg of 15 mg (7 %) | Pass | View |
| Mar 7, 2026 | TB-500 | 99.8 % | 10.6 mg of 10 mg (6 %) | Pass | View |
| Mar 6, 2026 | Ipamorelin | 99.9 % | 4.36 mg of 5 mg (-13 %) | Pass | View |
| Mar 2, 2026 | Tirzepatide | 99.9 % | 17.7 mg of 30 mg (-41 %) | Pass | View |
| Feb 26, 2026 | Retatrutide | 99.9 % | 9.75 mg of 10 mg (-3 %) | Pass | View |
| Feb 26, 2026 | BPC-157 | 99.88 % | 8.65 mg of 10 mg (-14 %) | Pass | View |
| Feb 18, 2026 | Tirzepatide | 99.38 % | 54.4 mg of 60 mg (-9 %) | Pass | View |
| Feb 18, 2026 | Tirzepatide | 99.14 % | 53.4 mg of 60 mg (-11 %) | Pass | View |
| Feb 15, 2026 | Retatrutide | 99.7 % | 10 mg of 10 mg (0 %) | Pass | View |
| Feb 11, 2026 | Tirzepatide | 99.9 % | 31.8 mg of 30 mg (6 %) | Pass | View |
| Feb 11, 2026 | Tesamorelin | 99.9 % | 11.6 mg of 10 mg (16 %) | Pass | View |
| Feb 9, 2026 | GHK-Cu | 99.9 % | 54.8 mg of 100 mg (-45 %) | Pass | View |
| Feb 4, 2026 | Tirzepatide | 99.8 % | 32.4 mg of 30 mg (8 %) | Pass | View |
| Feb 4, 2026 | GHK-Cu | 99.9 % | 54.9 mg of 100 mg (-45 %) | Pass | View |
| Jan 22, 2026 | Tirzepatide | 99.8 % | 30.8 mg of 30 mg (3 %) | Pass | View |
| Jan 22, 2026 | Tirzepatide | 99.8 % | 30.2 mg of 30 mg (1 %) | Pass | View |
| Jan 19, 2026 | Tesamorelin | 99.21 % | 10.3 mg of 10 mg (3 %) | Pass | View |
| Jan 19, 2026 | GHK-Cu | 99.95 % | 144 mg of 100 mg (44 %) | Pass | View |
| Jan 15, 2026 | Tirzepatide | 99.8 % | 18.5 mg of 30 mg (-38 %) | Pass | View |
| Jan 15, 2026 | BPC-157 | 98.6 % | 13.9 mg of 10 mg (39 %) | Pass | View |
| Jan 9, 2026 | Tesamorelin | 98.92 % | 9.63 mg of 10 mg (-4 %) | Pass | View |
| Jan 6, 2026 | GHK-Cu | 99.89 % | 48 mg of 50 mg (-4 %) | Pass | View |
| Jan 6, 2026 | GHK-Cu | 99.95 % | 49.4 mg of 50 mg (-1 %) | Pass | View |
| Dec 29, 2025 | Tirzepatide | 99.8 % | 78.3 mg of 60 mg (31 %) | Pass | View |
| Dec 29, 2025 | Tirzepatide | 99.95 % | 10.1 mg of 10 mg (1 %) | Pass | View |
| Dec 29, 2025 | Tirzepatide | 99.8 % | 45.8 mg of 40 mg (15 %) | Pass | View |
| Dec 29, 2025 | GHK-Cu | 99.95 % | 105 mg of 100 mg (5 %) | Pass | View |
| Dec 29, 2025 | PT-141 | 99.7 % | 8.5 mg of 10 mg (-15 %) | Pass | View |
| Dec 11, 2025 | Tesamorelin | 99.88 % | 6.45 mg of 5 mg (29 %) | Pass | View |
| Dec 11, 2025 | BPC-157 | 99.95 % | 7.85 mg of 10 mg (-22 %) | Pass | View |
| Nov 25, 2025 | Retatrutide | 99.95 % | 18.6 mg of 20 mg (-7 %) | Pass | View |
| Nov 25, 2025 | Tirzepatide | 99.95 % | 30.4 mg of 30 mg (1 %) | Pass | View |
| Nov 25, 2025 | Retatrutide | 99.95 % | 9.91 mg of 10 mg (-1 %) | Pass | View |
| Nov 25, 2025 | Retatrutide | 99.95 % | 19.6 mg of 20 mg (-2 %) | Pass | View |
| Nov 25, 2025 | BPC-157 | 99.95 % | 11.2 mg of 10 mg (12 %) | Pass | View |
| Nov 25, 2025 | GHK-Cu | 99.48 % | 48.3 mg of 50 mg (-3 %) | Pass | View |
| Nov 25, 2025 | GHK-Cu | 99.92 % | 115 mg of 100 mg (15 %) | Pass | View |
| Nov 25, 2025 | PT-141 | 99.17 % | 10.5 mg of 10 mg (5 %) | Pass | View |
What Xingruida XDR sells
No current listings on record.
About Xingruida XDR
Finnrick has tested 92 samples from Xingruida XDR across 9 products.